SinoMab BioScience Limited (“SinoMab” or the “Company”, stock code: 3681.HK) is committed to the exploration, development, production, and marketing of therapeutics for the management of immune system disorders. The Company’s leading product SM03 is a promising first-in-class mAb targeting CD22 for the treatment of rheumatoid arthritis and is presently undergoing Phase III clinical trials for rheumatoid arthritis in China, which has been acknowledged as one of the significant special initiatives of Significant New Drugs Development of the Thirteenth Five-Year Plan Period.
Sinomab Bioscience
Headquarters
Hong Kong